- Aptevo Therapeutics (NASDAQ:APVO) +35.7% after-hours following a disclosure that 42.5% shareholder Tang Capital Partners offered to buy the remaining shares for $50/share in cash.
- Shares have surged nearly 6x this month since announcing a complete remission in a Phase 1 clinical trial evaluating lead candidate APVO436 in patients with acute myeloid leukemia and myelodysplastic syndromes.
- Aptevo might be very close to being cash flow positive over the next 12 months, George Kesarios writes in a bullish analysis published recently on Seeking Alpha.
- https://seekingalpha.com/news/3637762-aptevo-gets-50-share-takeout-offer-from-shareholder-tang
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.